| Literature DB >> 28256094 |
Junki Sakata1, Ryoji Yoshida1, Yuichiro Matsuoka1, Masashi Nagata1, Akiyuki Hirosue1, Kenta Kawahara1, Takuya Nakamura1, Masafumi Nakamoto1, Masatoshi Hirayama1, Nozomu Takahashi1, Hikaru Nakashima1, Hidetaka Arita1, Hidenao Ogi1, Akimitsu Hiraki2, Masanori Shinohara3, Hideki Nakayama1.
Abstract
Oral leukoplakia (OL) is a common, potentially malignant disorder of the oral cavity. SMAD4 was initially identified as a tumor suppressor and central mediator of transforming growth factor (TGF)-β signaling. In this study, we aimed to determine the expression patterns of SMAD4 in OL, its relationship with the degree of inflammation, and its clinical implications as a biomarker for OL malignant transformation. A total of 150 patients with OL were enrolled in this study. Paraffin-embedded sections obtained from biopsy or resection specimens were subjected to immunohistochemical analysis. Associations among the status of epithelial SMAD4 expression, stromal lymphocyte infiltration, and malignant transformation of OL were examined. Malignant transformation was significantly associated with the status of SMAD4 expression (P = 0.0017) and lymphocyte infiltration status (P = 0.0054). Cox regression analysis, based on the event-free survival (EFS), revealed that a low SMAD4 expression was a significant prognostic factor in OL patients (hazard ratio, 2.632; P = 0.043). In addition, a low SMAD4 expression was closely correlated with high lymphocyte infiltration (P = 0.00035), resulting in a significant correlation between the combination of low SMAD4 expression and high lymphocyte infiltration with malignant transformation of OL (P = 0.00027). The combination of the status of epithelial SMAD4 expression and stromal lymphocyte infiltration may be a useful biomarker for predicting malignant transformation in OL patients. These results suggest that not only epithelial SMAD4 loss, but also stromal features, may regulate the risk of malignant transformation of OL.Entities:
Keywords: Lymphocyte infiltration; SMAD4; malignant transformation; oral leukoplakia; oral squamous cell carcinoma
Mesh:
Substances:
Year: 2017 PMID: 28256094 PMCID: PMC5387127 DOI: 10.1002/cam4.1005
Source DB: PubMed Journal: Cancer Med ISSN: 2045-7634 Impact factor: 4.452
Figure 1Immunohistochemical staining of SMAD4 in oral leukoplakia and oral squamous cell carcinoma tissues. (A) Representative immunohistochemical staining patterns of SMAD4 are shown according to the expression status. The sections were stained with hematoxylin and eosin (H&E) and anti‐SMAD4 polyclonal antibodies. In the oral leukoplakia (OL) specimens, SMAD4 was mainly expressed in the nucleus of the epithelial cells. Original magnification, ×200, scale bar = 100 μm. (B) Immunostaining scores obtained from each pathological group were calculated and statistically analyzed by the Mann–Whitney U test. The y axis shows the mean values of the SMAD4 immunostaining scores. **, P < 0.01 oral squamous cell carcinoma, OSCC.
Correlation between malignant transformation and clinicopathological factors in 150 oral leukoplakia patients
| Characteristics | Total | Malignant transformation |
| |
|---|---|---|---|---|
| Yes | No | |||
| 150 | 23 (15.3) | 127 (84.7) | ||
| Age (years) | ||||
| Median | 62.3 | 66 | 61.7 | |
| Range | 19–87 | 47–87 | 19–87 | |
| ≤65 | 85 | 12 (14.1) | 73 (85.9) | 0.637 |
| >65 | 65 | 11 (16.9) | 54 (83.1) | |
| Sex | ||||
| Male | 76 | 9 (11.8) | 67 (88.2) | 0.229 |
| Female | 74 | 14 (18.9) | 60 (81.1) | |
| Oral subsite | ||||
| Gingiva | 64 | 11 (17.2) | 53 (82.8) | 0.128 |
| Tongue | 52 | 11 (21.2) | 41 (78.8) | |
| Buccal mucosa | 21 | 1 (4.8) | 20 (95.2) | |
| Others | 13 | 0 (0) | 13 (100) | |
| Grade of dysplasia | ||||
| None | 101 | 13 (12.9) | 88 (87.1) | 0.427 |
| Mild | 37 | 7 (18.9) | 30 (81.1) | |
| Moderate, severe | 12 | 3 (25.0) | 9 (75.0) | |
| SMAD4 expression | ||||
| High | 84 | 6 (7.1) | 78 (92.9) | 0.0017 |
| Low | 66 | 17 (25.8) | 49 (74.2) | |
| Lymphocyte infiltration | ||||
| Low | 51 | 2 (3.9) | 49 (96.1) | 0.0054 |
| High | 99 | 21 (21.2) | 78 (78.8) | |
The chi‐square test was used to examine the correlation between malignant transformation and clinicopathological factors in 150 oral leukoplakia patients.
P < 0.01.
Figure 2SMAD4 expression status affects the malignant transformation rate of oral leukoplakia. In the Kaplan–Meier survival analysis of patients with oral leukoplakia ( OL), patients were divided into two groups based on the SMAD4 immunostaining scores (‐low or ‐high expression groups) or the lymphocyte infiltration status (lymphocyte infiltration‐low or ‐high groups). (A) Event‐free survival (EFS) of the 150 OL patients based on the status of SMAD4 expression. *, P < 0.05. (B) EFS of the 150 OL patients based on the status of lymphocyte infiltration. NS, no significance.
The results of the multivariate analysis of malignant transformation factors by the Cox proportional hazards regression model
| Characteristics | Assigned score | Event‐free survival |
|
|---|---|---|---|
| Hazard ratio (95% CI) | |||
| Age (years) | |||
| ≤65 | 0 | 1.902 (0.794–4.902) | 0.151 |
| >65 | 1 | ||
| Sex | |||
| Male | 0 | 1.098 (0.469–2.705) | 0.831 |
| Female | 1 | ||
| Oral subsite | |||
| Tongue | 0 | 1.305 (0.546–3.151) | 0.547 |
| Others | 1 | ||
| Grade of dysplasia | |||
| None | 0 | 1.191 (0.492–2.792) | 0.689 |
| Mild, moderate, severe | 1 | ||
| SMAD4 expression | |||
| High | 0 | 2.632 (1.031–7.654) | 0.043 |
| Low | 1 | ||
| Lymphocyte infiltration | |||
| Low | 0 | 2.670 (0.729–17.24) | 0.152 |
| High | 1 | ||
CI, confidence interval.
P < 0.05.
Correlation between SMAD4 expression and clinicopathological factors in 150 oral leukoplakia patients
| Characteristics | Total | SMAD4 expression |
| |
|---|---|---|---|---|
| High | Low | |||
| 150 | 84 (56.0) | 66 (44.0) | ||
| Age (years) | ||||
| Median | 62.3 | 66 | 61.7 | |
| Range | 19–87 | 47–87 | 19–87 | |
| ≤65 | 85 | 49 (57.6) | 36 (42.4) | 0.642 |
| >65 | 65 | 35 (53.8) | 30 (46.2) | |
| Sex | ||||
| Male | 76 | 42 (11.7) | 34 (88.3) | 0.854 |
| Female | 74 | 42 (19.2) | 32 (80.8) | |
| Oral subsite | ||||
| Gingiva | 64 | 33 (51.6) | 31 (48.4) | 0.586 |
| Tongue | 52 | 25 (48.1) | 27 (51.9) | |
| Buccal mucosa | 21 | 14 (66.7) | 7 (33.3) | |
| Others | 13 | 12 (92.3) | 1 (0.08) | |
| Grade of dysplasia | ||||
| None | 101 | 55 (54.5) | 46 (45.5) | 0.859 |
| Mild | 37 | 22 (59.5) | 15 (40.5) | |
| Moderate, severe | 12 | 7 (58.3) | 5 (41.7) | |
| Lymphocyte infiltration | ||||
| Low | 51 | 39 (76.5) | 12 (23.5) | 0.00029 |
| High | 99 | 45 (45.5) | 54 (54.5) | |
The chi‐square test was used to examine the correlation between SMAD4 expression and clinicopathological factors in 150 OL patients.
P < 0.01.
Figure 3Reduction of SMAD4 expression is correlated with inflammatory stromal features. Representative immunohistochemical staining patterns of SMAD4 and the status of lymphocyte infiltration are shown according to the expression status. The sections were stained with hematoxylin and eosin (H&E) and anti‐SMAD4 polyclonal antibodies. Original magnification, ×100, scale bar = 50 μm.
Correlation between malignant transformation and the combination of SMAD4 expression and lymphocyte infiltration in 150 oral leukoplakia patients
| Characteristics | Total | Malignant transformation |
| |
|---|---|---|---|---|
| Yes | No | |||
| 150 | 23 (15.3) | 127 (84.7) | ||
| SMAD4‐low and lymphocyte infiltration‐high | 54 | 16 (29.6) | 38 (70.3) | 0.00027 |
| Others | 96 | 7 (7.3) | 89 (92.7) | |
The chi‐square test was used to examine the correlation between malignant transformation and the combination of SMAD4 expression and lymphocyte infiltration in 150 OL patients.
P < 0.01.
Figure 4Combination of SMAD4 expression and lymphocyte infiltration status is useful predictive marker for the malignant transformation of oral leukoplakia. In the Kaplan–Meier survival analysis of patients with oral leukoplakia (OL), patients were divided into two groups. One group was the patients with SMAD4‐low expression and lymphocyte infiltration‐high, and the other group was all other combinations. The graph shows the event‐free survival (EFS) of the 150 patients with OL based on the status of SMAD4 expression and lymphocyte infiltration. *, P < 0.05.